North Bay Neuroscience Institute
- Assets
- $0.0
- Revenue
- $0.0
- Investments
- $0.0
- Employees
- 5
- Location
- Sebastopol, CA
- Founding
- 06/2019
- Data as of
- 12/2020
- EIN
- 83-1580566
Organization Overview
North Bay Neuroscience Institute is located in Sebastopol, CA. The organization was established in 2019. According to its NTEE Classification (H90) the organization is classified as: Medical Disciplines Research, under the broad grouping of Medical Research and related organizations. As of 12/2020, North Bay Neuroscience Institute employed 5 individuals. North Bay Neuroscience Institute is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2020, North Bay Neuroscience Institute generated $60.2k in total revenue. This represents a relatively dramatic decline in revenue. Over the past 2 years, the organization has seen revenues fall by an average of (73.9%) each year. All expenses for the organization totaled $313.0k during the year ending 12/2020. You can explore the organizations financials more deeply in the financial statements section below.
Form
990EZ
Mission & Program ActivityExcerpts From the 990EZ Filing
TAX YEAR
2020
Describe the Organization's Mission:
Part 3 - Line 1
OUR WORK INVOLVES RESEARCHING DIFFERENT POTENTIAL MEDICINES THAT MAY IMPACT THE ONSET OF ALZHEIMERS DISEASE. WE WORK WITH PHARMACEUTICAL COMPANIES WHICH ARE IN VARIOUS TRIAL STAGES OF DEVELOPING THESE NEW DRUGS. OUR JOB IS TO WORK WITH PATIENTS SUBJECTS WHO HAVE EARLY ALZHEIMER INDICATIONS AND WANT TO TRY THESE TRIAL DRUGS. THEIR PARTICIPATION IN THESE STUDIES HELPS US ALL UNDERSTAND WAYS TO BEAT ALZHEIMERS DISEASE.
Describe the Organization's Program Activity:
Part 3
NOVARTIS: GENERATION 1 & 2 - TESTS THE SAFETY AND EFFECTS OF THE INVESTGATIONAL DRUG CNP520 IN COGNITIVELY NORMAL OLDER ADULTS WHO ARE AT RISK OF DEVELOPING DEMENTIA BASED ON THEIR AGE, GENETIC STATUS, AND BRAIN AMYLOID LEVELS.
BIOGEN: EMERGE STUDY - EVALUATES THE EFFICACY OF THE EXPERIMENTAL DRUG ADUCANUMAB COMPARED WITH A PLACEBO IN SLOWING COGNITIVE AND FUNCTIONAL IMPAIRMENT IN PEOPLE WITH EARLY-STAGE ALZHEIMER'S DISEASE.
ROCHE: CREAD - THIS CLINICAL TRIAL TESTS THE EXPERIMENTAL DRUG CRENEZUMAB IN PEOPLE WITH EARLY TO MILD ALZHEIMER'S DISEASE. IT ASSESSES THE DRUG'S SAFETY AND EFFICACY AND EVALUATES ANY CHANGES IN PARTICIAPANTS' DEMENTIA RATING AND PERFORMANMCE ON NEUROPSYCHOLOGICAL TESTS.
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
PDF Copies of 990 Filings
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
Maben Rainwater Executive Dir. | 40 | $52,500 | |
Beth Bollinger Chairman | 1 | $0 | |
Soraya Saffarinia Secretary | 0 | $0 | |
Terry Hess Foundation Mgr. | 40 | $93,417 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Total Revenue from Contributions, Gifts, Grants & Similar | $0 |
| Total Program Service Revenue | $61,711 |
| Membership dues | $0 |
| Investment income | $0 |
| Gain or Loss | -$1,489 |
| Net Income from Gaming & Fundraising | $0 |
| Other Revenue | $0 |
| Total Revenue | $60,222 |
| Statement of Expenses | |
|---|---|
| Grants and similar amounts paid | $0 |
| Benefits paid to or for members | $0 |
| Salaries, other compensation, and employee benefits | $217,393 |
| Professional fees and other payments to independent contractors | $3,000 |
| Occupancy, rent, utilities, and maintenance | $73,508 |
| Printing, publications, postage, and shipping | $0 |
| Other expenses | $19,050 |
| Total expenses | $312,951 |
| Balance Sheet | |
|---|---|
| Cash, savings, and investments | $0 |
| Other assets | $0 |
| Total assets | $0 |
| Total liabilities | $0 |
| Net assets or fund balances | $0 |